Article
Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
Archives of virology - 1 Oct 2020
Safarnezhad Tameshkel Fahimeh, Karbalaie Niya Mohammad Hadi, Zamani Farhad, Motamed Nima, Ajdarkosh Hossein, Vafaeimanesh Jamshid, Khoonsari Mahmoodreza, Sohrabi Masood Reza, Aten Sima, Azarkeivan Azita, Eslami Masoumeh Sadat, Perumal Dhayaneethie, Maadi Mansooreh, Ghanbari Behrooz, Keyvani Hossein
Abstract excerpt
Patients with thalassemia major are at high risk of hepatitis C through blood transfusion from donors infected by hepatitis C virus (HCV). The use of direct-acting antiviral (DAA) therapy against such HCV infections has increased in different populations. However, resistant viral variants can affect treatment outcomes, and therefore improved surveillance strategies are needed. Accordingly, we aimed to evaluate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.